The majority of opinion-leading oncologists worldwide agree that combination therapy offers tremendous potential for extending the lifespan of – and ultimately curing – cancer patients. The evolution of combination immunomodulatory approaches promises to maximise treatment outcomes and overcome most tumours’ resistance mechanisms to single-agent immunotherapy.
Cancure has developed its own potential breakthrough immunotherapies. Genvax formulations specific for each target indication and Galectin CNC225 can be combined with an ICI to achieve unprecedented response rates in a range of major cancer indications, including breast and colon cancer.
The powerful combination of a Genvax formulation and Galectin CNC225 with an immune checkpoint inhibitor (anti-CTLA4) resulted in an experimental “cure” for colon cancer, with 100% survival of mice receiving the triple combination. These results are extremely compelling.